Efzimfotase Alfa Still Tapped As Strensiq Successor Despite Mixed Phase III Results
AstraZeneca’s Alexion rare disease unit still expects the hypophosphatasia drug, meant as a successor to the older enzyme replacement therapy, to be a blockbuster.
Scrip - October 12, 2026

Humotech Hopes Blinded Data Will Draw Insurance Coverage For Robotic Prosthetic Foot Trial Service
Humotech’s mobile clinic lets amputees try out prosthetic feet via a robotic system without knowing which model they are testing. CEO Josh Caputo hopes the data will win further insurance coverage for the service, which is currently covered by one undisclosed payer.
Medtech Insight - October 12, 2026

Saunders B+L Exit Is A Surprise, Bausch Health CEO Appio Steps In
Bausch + Lomb board chairman and Bausch Health CEO Thomas Appio has been appointed interim CEO effective immediately. Bausch Health retains a majority ownership in B+L.
Scrip - October 12, 2026

FDA Early Alert: Eight Injuries, Four Deaths Associated With Philips Lumify System
The US FDA has issued an early alert concerning connectivity issues with the Philips Lumify ultrasound system that may interrupt scans and delay care. The company reports eight serious injuries and four deaths associated with the issue. Philips says it is developing an updated software.
Medtech Insight - October 12, 2026

Execs On The Move: September 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - October 12, 2026

Endeavor Plays To WHISTLE-PF After Taladegib Lung Disease Win
The hedgehog pathway inhibitor licensed from Eli Lilly is heading to Phase III.
Scrip - October 12, 2026

Outlook Promotes Eylea Executive To Helm Lytenava Launch
Outlook Therapeutics has promoted to the role of chief commercial officer Greg DiPasquale – who has previously been instrumental in brand launches such as Beovu, Eylea, Eylea HD and Triesence – in preparation for its US launch of Lytenava.
Generics Bulletin - October 12, 2026

Rethinking Success in Neuroscience Clinical Development
Learn how advances in biomarkers, AI, and trial design are helping sponsors improve decision-making across neuroscience programmes.
Scrip - October 12, 2026

Thyme Therapeutics Announces Plans To Build A Lower-Cost Oncology Biosimilars Model
US-based Thyme Companies has announced the launch of biosimilars venture Thyme Therapeutics to establish a new sustainable approach to the commercialization of oncology products.
Generics Bulletin - October 12, 2026

Pipeline Watch: Eli Lilly’s Jaypirca Wins Approval in First-Line Chronic Lymphocytic Leukemia
Genmab and AbbVie’s Epkinly plus R-CHOP improves progression-free survival in Phase III EPCORE DLBCL-2, and Zealand and Roche’s petrelintide meets the Phase II ZUPREME-2 primary endpoint.
Scrip - October 12, 2026

Italfarmaco Adds Hunter Syndrome To Rare Disease Portfolio With JCR Deal
JR-141 gives Italfarmaco a late-stage Hunter syndrome asset, with Phase III under way and no filing dates disclosed.
Scrip - October 12, 2026

Full Results Take Shine Off Merck’s Eye Drug Challenger
Merck still hopes remigromig can be a blockbuster, but full Phase III trial results show less obvious benefits for patients from its novel mechanism compared with an older anti-VEGF therapy
Scrip - October 12, 2026

FDA Consumer Health Advisory: CRN Continuing Fight Against Sales Restrictions
What's happening, why it matters and what's next at FDA. This edition explores CRN's efforts to challenge age-restricted supplement sales laws; warning letters for unapproved STI claims; and pressure on Revlon to address talc-testing deficiencies identified by the agency.
HBW Insight - October 12, 2026

EU Will Make Standards Free, Faster And AI-Ready After CJEU Ruling
New regulation could save companies €30m while addressing MDR and AI Act standards backlog.
Medtech Insight - October 12, 2026

MHRA AI Rules Get Thumbs Up From Digital Experts As UK Builds ‘Frictionless’ Regulator
Speakers at the ABHI Digital Health Conference reflected on the UK MHRA’s future as AI changes the game both externally and internally.
Medtech Insight - October 12, 2026

LSX USA: China Will Dominate Years 4–12 Of Drug Development, Say Investors
Investors described a relay in which the US leads early science, China leads mid-stage development and the US returns for late-stage trials and commercialization, with licensing structure, policy risk and pricing shaping who benefits.
In Vivo - October 12, 2026

Raynovent’s Global-First Biweekly GLP-1/GIP Looking Solid In Topline Obesity Readout
Raynovent's first-in-class, biweekly injected GLP-1/GIP dual agonist shows 22% body weight reduction at highest dose at 52 weeks in China Phase III trial.
Scrip - October 12, 2026

NDIN Guidance, Drug Exclusion Provision On FDA To-Do List – ‘Old’ Ingredient List Is Industry Job
ODSP director Cara Welch discussed NDIN guidance, drug exclusion provision, “old” ingredient list, defining dietary substances allowed for use in supplements and elimination of self-affirmed GRAS during Council for Responsible Nutrition conference.
HBW Insight - October 12, 2026